Thursday, March 08, 2018

NAD+

Top aging expert says these 4 FDA-approved drugs hold promise for extending life PDF paper Gerotherapy: GLP-1 - calorie restriction, SGLT2 inhibitors to remove sugar from the kidneys through urine, Bisphosphonates - osteoporosis, Metformin - insulin sensitivity 

A primer on the current state of longevity researchsirtuins - NAD+ (NMN, NR, resveratrol, fisetin, quercetin), cellular reprogramming, biological clocks (grip strength, graying hair, wrinkled skin, epigenetic: Horvath's clock, telomere, transcriptomics, proteomics) 

* 2024 Scientists find humans age dramatically in two bursts – at 44, then 60 The first wave of changes included molecules linked to cardiovascular disease and the ability to metabolise caffeine, alcohol and lipids. The second wave of changes included molecules involved in immune regulation, carbohydrate metabolism and kidney function.  
* 2024 Massive biomolecular shifts occur in our 40s and 60s, Stanford Medicine researchers find, Nonlinear dynamics of multi-omics profiles during human aging, In people in their 40s, significant changes were seen in the number of molecules related to alcohol, caffeine and lipid metabolism; cardiovascular disease; and skin and muscle. In those in their 60s, changes were related to carbohydrate and caffeine metabolism, immune regulation, kidney function, cardiovascular disease, and skin and muscle. 

Centenarian blood tests give hints of the secrets to longevity: glucose, creatinine, uric acid, cholesterol, iron, TIBC, liver (Alat, Asat, albumin, GGT, Alp, LD) 




Nicotinamide adenine dinucleotide NAD
Beyond Resveratrol: The Anti-Aging NAD Fad
Star research team maps nr and nmn conversion path to cellular nad 

Nicotinamide riboside (NR), ChromaDex Niagen (about niagen) Truniagen, Elysium Health (Basis), HPN Niagen, Life Extension NAD+ Cell Regenerator, with Resveratrol 

Nicotinamide mononucleotide (NMN/菸醯胺單核苷酸 500mg)The Science Behind NMN–A Stable, Reliable NAD+Activator and Anti-Aging Molecule (liposomal NMN), Scientists identify new fuel-delivery route for cellsDavid Sinclair, Human trials of NMN therapy, Alive by Nature 

No comments: